Zoom tumbles 16% as Pfizer's vaccine success drags on work-from-home stocks

Carl Court/Getty Images
  • Zoom dove as much as 16% in early Monday trading after Pfizer’s encouraging COVID-19 drug results dragged stay-at-home stocks lower.
  • The pharmaceutical company announced Monday morning that it’s experimental coronavirus drug was more than 90% effective in preventing COVID-19 in trial participants.
  • The news lifted global stocks, particularly those for firms hit hardest by the pandemic like airlines and hotels.
  • Conversely, stay-at-home names including Zoom, DocuSign, and Peloton tumbled as investors bet on the vaccine bringing an end to the global health crisis.
  • Watch Zoom trade live here.

Zoom Video Communications slid as much as 16% in early Monday trading as Pfizer’s encouraging COVID-19 vaccine news prompted the outsized selling of so-called stay-at-home stocks.

The US pharmaceutical giant announced Monday morning that its experimental coronavirus vaccine, created in collaboration with BioNTech, was more than 90% effective in preventing COVID-19 in trial participants. Pfizer said it will apply to the US Food and Drug Administration for emergency-use authorization, a process that would allow for a faster rollout of the vaccine.

The positive news fuelled new hopes that a viable coronavirus drug can end the global health crisis. US stock futures surged higher. Industries slammed hardest by the virus, including airlines, hotels, and cruises, rallied in early trading.

Conversely, companies that thrived through quarantine orders and prolonged stay-at-home activity tanked. DocuSign,Peloton, and Wayfair joined Zoom and others in the sell-off as investors boosted bets on a safe reopening.

Read more:
Morgan Stanley says to load up on these 10 stocks featured on the firm’s ‘buy list,’ which has dominated the broader market this year

Zoom was among the market’s biggest winners through the year as its video conferencing software became ubiquitous with telecommuting. The company’s shares closed at $US500.11 on Friday, up nearly 650% year-to-date.

Monday’s slump places the stock at its lowest since late September.

The stay-at-home group’s plunge repeats a trading pattern seen after the release of similarly positive vaccine updates. Promising data from Gilead, Moderna, and AstraZeneca’s drug trials dragged on telecommuting stocks earlier in the year. The stocks tended to rise when vaccine candidates failed trials or virus cases trended higher.

With the world facing a resurgence in coronavirus infections and several advanced economies entering new lockdowns, Pfizer’s announcement cuts into strong momentum for Zoom shares.

Now read more markets coverage from Markets Insider and Business Insider:

‘It is going to be very, very bad’: Legendary investor Jim Rogers says the US debt load is creating a prime environment for a collapse — and warns the next market blow off will be worse than the Financial Crisis’ 50% decline

These are the market’s biggest winners and losers of a hectic election week

US economy beats forecasts, adds 638,000 jobs in October as unemployment falls to 6.9%

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.